Christoph C. Carter, MD, PhD

Director, Clinical Research (MD)
Gilead Sciences, Inc.

Disclosure(s): Aspire Scientific: Medical writing support; Gilead Sciences, Inc.: Medical writing support and Employee, Stocks/Bonds (Public Company)

Poster(s):

• (P-299) No Clinically Significant Drug-Drug Interactions Between Lenacapavir and Hormonal Contraceptives in PURPOSE 1
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-305) No Clinically Significant Drug–Drug Interactions with Co-administration of Feminizing or Masculinizing Hormone Therapy and Twice-yearly Lenacapavir PrEP in Gender-Diverse Persons
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET